Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s11102-014-0624-3 http://scihub22266oqcxt.onion/10.1007/s11102-014-0624-3 C4376561!4376561 !25534889     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=25534889 &cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\25534889 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Pituitary 2015 ; 18 (2 ): 225-31 Nephropedia Template TP {{tp|p=25534889 |t=2015. Silent corticotroph adenomas |pdf=|usr=}}{{25534889 }} gab.com Text Silent corticotroph adenomas JO: Pituitary http://www.kidney.de/pget.php?&tw=1&pmid=25534889 #FOAvip PURPOSE: Silent corticotroph adenomas (SCAs) comprise 20% of all corticotroph adenomas and 3-19% of nonfunctioning adenomas (NFAs). As they do not manifest clinical or biochemical hypercortisolism, they are diagnosed after pathologic examination of resected tumor tissue demonstrates positive ACTH expression. While preoperative features are similar to those of NFAs, SCAs may have more cavernous sinus invasion. Further, patients with SCAs tend to have more frequent and earlier recurrences than those with NFAs, often necessitating multiple surgeries and other modalities of treatment. This article reviews the incidence, pathogenesis, and clinical behavior of SCAs. METHODS: A systematic literature review was performed using PubMed for information regarding SCAs. RESULTS: Up to date findings regarding epidemiology, pathogenesis, pathology, clinical presentation, postoperative course, and management of patients with SCAs are presented. CONCLUSION: This review highlights the necessity of rigorous monitoring for recurrences and hypopituitarism in patients with SCAs. Twit Text FOAVip Silent corticotroph adenomas ????Pituitary http://www.kidney.de/pget.php?&tw=1&pmid=25534889 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25534889 #FOAvip English Wikipedia <ref>{{Cite pmid|25534889 }}</ref> Silent corticotroph adenomas #MMPMID25534889 Cooper O Pituitary 2015[Apr]; 18 (2 ): 225-31 PMID25534889 show ga PURPOSE: Silent corticotroph adenomas (SCAs) comprise 20% of all corticotroph adenomas and 3-19% of nonfunctioning adenomas (NFAs). As they do not manifest clinical or biochemical hypercortisolism, they are diagnosed after pathologic examination of resected tumor tissue demonstrates positive ACTH expression. While preoperative features are similar to those of NFAs, SCAs may have more cavernous sinus invasion. Further, patients with SCAs tend to have more frequent and earlier recurrences than those with NFAs, often necessitating multiple surgeries and other modalities of treatment. This article reviews the incidence, pathogenesis, and clinical behavior of SCAs. METHODS: A systematic literature review was performed using PubMed for information regarding SCAs. RESULTS: Up to date findings regarding epidemiology, pathogenesis, pathology, clinical presentation, postoperative course, and management of patients with SCAs are presented. CONCLUSION: This review highlights the necessity of rigorous monitoring for recurrences and hypopituitarism in patients with SCAs. |*ACTH-Secreting Pituitary Adenoma/epidemiology/pathology/surgery [MESH] |*Adenoma/epidemiology/pathology/surgery [MESH] |Asymptomatic Diseases [MESH] |Humans [MESH] |Neoplasm Recurrence, Local [MESH]Silent corticotroph adenomas (epmc).pdf DeepDyve Pubget Overpricing